JAMA (Journal of the American Medical Association) reported that the FDA recently approved a new HIV drug, dolutegravir (Tivicay). This new integrase strand transfer inhibitor was studied in 4 clinical trials which enrolled 2,539 patients. This medication helps reduce the viral load by interfering with virus replication. The drug has been approved for use in adults 12 years or older who are new to the therapy or can be administered concurrently with existing anti-retroviral agents. Patients must weigh at least 40kg, and be naïve to integrase strand transfer inhibitors. Adverse effects include insomnia, headache, and more serious reactions such as hypersensitivity and abnormal liver function. The clinical trials also documented kidney problems for which the FDA is requiring post-marketing surveillance to assess the true risk. How do you think dolutegravir will affect current standard of care for HIV?
Click here for additional information.
Image courtesy of [jscreationzs] / FreeDigitalPhotos.net